🔬 We've been showcasing exceptional research from our #Highlights2025 collection. Today, we're proud to share the final featured article: Nanoscale engagement of programmed death ligand 1 (PD-L1) in membrane lipid raft domains of cancer cells ➡️ buff.ly/zGeaRmy
#PDL1 #lipidrafts #STED

🎯 4 dianas clave.
🧬 Tratamiento de precisión.
🌍 Impacto global.

📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#CáncerDePulmón #CáncerDePulmónNoMicrocítico #NSCLC #Oncología #OncologíaClínica #SaludGlobal #EGFR #ALK #PD1 #PDL1 #KRAS #KRASG12C #DengYueMedicinasEnHongKong

Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform Statement of Significance: We discovered a common light chain (CLC) bispecific antibody targeting PD-1 and PD-L1 with favorable biophysical properties and

Antibody Therapeutics(IF=4.5, Oxford University Press)
🎯🎯Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform
academic.oup.com/abt/article/...
#PD1 #PDL1 #YeastDisplay #Hybridoma

A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy Statement of Significance This project developed CVL006, a PD-L1/VEGF bispecific antibody combining an anti-PD-L1 VHH domain with an anti-VEGF IgG1. Precli

Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy
academic.oup.com/abt/article/...
#BispecificAntibody #PDL1 #VEGF

1/ J'ai dû passer genre 10 heures supplémentaires à me taper les séances de la consulation sur la #ConstitutionDuQuébec ( #pdl1 ). Dedans, plusieurs orgs. de droite exigent que le gouv. Qc exerce son droit de retrait pour empêcher les org. antiracistes/intersectionnels d'être financés par le féd.

Redirecting

🦷🧬 Just published online in JPS❣️
“Orai1- and STIM1-mediated calcium signaling controls PD-L1 expression and modulates antitumor immunity in oral cancer”
— Eriko Yamashita et al.
🔗 doi.org/10.1016/j.jp...
#CalciumSignaling #TumorImmunity #PDL1 #OralCancer #NowOnline #JPhysiolSci

#SummitTherapeutics has moved ahead in the race to bring a therapy targeting both #VEGF and #PDL1 to market, after the #FDA started a review of its ivonescimab drug for #lungcancer.

buff.ly/PtZy4pn

Standard #CRISPR couldn’t crack a #PDL1 knockout in #PC3 cells at the #UniPadova #UniversityPadua.
#CellEDIT’s direct nuclear injection enabled a verified homozygous #KO and rapid validation. 👉 https://bit.ly/4bInAg4

#GeneEditing #AdoptiveCellTherapy #ProstateCancer #CancerResearch #Biotech

🧬 Nueva opción en cáncer gástrico avanzado
✔️ #RetlirafuspAlfa aprobado
✔️ Inmunoterapia de doble diana
✔️ Tratamiento de primera línea

📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#Aizeli #CáncerGástrico #CáncerAvanzado #CáncerMetastásico #PDL1 #CPS #DengYueMedicinasEnHongKong

🔥#meTPD–Driven Cancer #Vaccine
#iVAC degrades #PDL1, drives tumor antigen presentation, and reprograms cells into APC-like messengers. Awakens bystander memory #Tcells, turning cold tumors hot—robust CD8⁺ activation & superior tumor control in humanized mice & organoids.
#TPD

#JiangsuHengruiPharma has chalked up a first-in-class approval for retlirafusp alfa, a #bifunctionaldrug that targets #PDL1 and #TGFbeta, as a treatment for advanced #gastriccancer.

pharmaphorum.com/news/hengrui...

Engineered extracellular vesicles reprogram T cells by targeting PD-1 and PHB1 signaling in inflammatory bowel disease - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Engineered extracellular vesicles reprogram T cells by targeting PD-1 and PHB1 signaling in inflammatory bowel disease

A #bioengineered #ExtracellularVesicle therapy with #PDL1 and #miR27a3p reprograms T‑cell immunity in #InflammatoryBowelDisease by suppressing Th17 #bioenergetics, expanding #Tregs, reducing inflammation, and preserving gut epithelial integrity.

#STTT: doi.org/10.1038/s413...

💉 China aprueba #BecotatugVedotin
👩‍⚕️👨‍⚕️ Para pacientes adultos con:
• Cáncer de nasofaringe avanzado
– #PD1 / #PDL1
📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#ADC #CáncerDeCabezaYCuello #CáncerMetastásico #CáncerAvanzado #DengYueMedicinasEnHongKong

🎥 What is a biomarker? Dr. Meera Patel explains biomarkers and PD-L1 testing—and how to talk about them with your doctor.

#LungCancer #Biomarker #PDL1 #LungCancerOncTalk2025 #CancerGRACE #LungCancerInformation

La NMPA de China aprueba condicionalmente las cápsulas de Tunlametinib

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Tunlametinib #Keluping #NMPA #China #Melanoma #NRAS #PD1 #PDL1 #InhibidorMEK #InnovaciónFarmacéutica #AprobaciónCondicional

Immunotherapy With Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors in Patients With Advanced Non–Small Cell Lung Cancers: A Multicenter, Retrospective Analysis The graphic abstract presents a retrospective study focused on lung cancer immunotherapy, carried out across five hospitals. It evaluates the efficacy of PD-1 versus PD-L1 inhibitors in treating non–...

#Article in #MedComm
Immunotherapy With Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors in Patients With Advanced Non–Small Cell Lung Cancers: A #Multicenter, #Retrospective Analysis doi.org/10.1002/mco2...

#immunotherapy #LungCancer #PD1 #PDL1

China NMPA Approves Tagitanlimab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#TagitanlimabInjection #Tagitanlimab #Ketaille #NMPAApproval #NasopharyngealCancer #NPC #Immunotherapy #PDL1 #MonoclonalAntibody #KelunBiotech

Combining the mTORC1/2 inhibitor #onatasertib with the #PD1antibody #toripalimab offers a manageable safety profile and promising efficacy in advanced #SolidTumors—especially recurrent or #MetastaticCervicalCancer—regardless of #PDL1 expression.

#STTT: doi.org/10.1038/s413...

💪 Small in size, strong in performance
Anti-PD-L1 VHH Antibody (JOT0002-5) by Jotbody: precise PD-L1 detection (ELISA/WB/IHC/IF/FC), 14.4 kDa, KD=0.363 nM. Ideal for research & diagnostics.
#PDL1 #VHH #nanobody #lifescience #biotech #researchtools

🧬 Molecule of the Moment: #mRNA4359 + #pembrolizumab
At #ESMO2025, #Moderna reported early Phase 1/2 data showing mRNA-4359 may overcome checkpoint inhibitor–resistant #melanoma by targeting #PDL1 & #IDO1 pathways. Combo with pembrolizumab showed manageable safety, no new immune AEs.

Client Challenge

💡 Dual degradation helps overcome drug resistance in breast cancer and restores immune response in resistant models.
www.nature.com/articles/s41...

#DrugResistance #OncologyResearch #CancerBiology #EGFR #HER2 #PDL1 #VISTA

Paper out in Biomedicine & Pharmacotherapy! 🔬🧑‍🔬👩🏼‍🔬
“Light-enhanced cytotoxicity & trafficking of the PD-L1-targeting photoimmunoconjugate EITC-atezolizumab” 👉 lnkd.in/dz-zF-Hx Novel: #Atezolizumab clusters w/ #CD63 pos #MVBs
#Photoimmunotherapy #lungcancer
#PDL1 #Tecentriq #NSCLC #PhotodynamicTherapy

Using an IO dataset of #nivolumab-treated renal cancer patients, we found that:
- #PD1 or #PDL1 expression didn't predict survival
- PD1 activity (from RIDDEN) did associate with survival.
Showing that receptor activity could be a more effective biomarker than expression. 5/n

#ESMOGI25: A combination of givastomig, nivolumab and mFOLFOX shows promising activity and acceptable safety in HER2− CLDN18.2+ #GastroEsophagealCancer, regardless of #PDL1 or CLDN18.2 status.

Further details in the #ESMODailyReporter

🔗 buff.ly/hKBZtJZ

Featured today by @MSKLibrary: First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab, in patients with advanced malignancies
dx.doi.org/10.1016/j.es...

#FAZ053 #PDL1 #ClinicalTrials #FirstInHuman

🧭 Biomarkers are crucial for predicting who benefits from anti-PD-1/L1/CTLA-4 treatments.

@cp-cancercell.bsky.social

#Onco404 #Cancer #Kanser #Immunotherapy #İmmünoterapi #MedSky #OncSky #Biomarkers #PrecisionOncology #PDL1 #TMB #MSI

www.ncbi.nlm.nih.gov/pmc/articles...

"Another benzimidazole compound, #albendazole, was able to target ubiquilin-4, a protein that interacts with and stabilizes #PDL1, thus promoting its proteasomal degradation."

www.ncbi.nlm.nih.gov/pmc/articles...

"In this regard, the halogenated salicylanilide compound #niclosamide was found to affect Signal Transducer and Activator of Transcription 3 ( #STAT3) phosphorylation and related #PDL1 expression in oncogene-addicted advanced-stage NSCLC patients,"

The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation - PubMed The incidence of melanoma is increasing faster than any other cancer. In recent years, treatment of melanoma and a range of other deadly cancers has involved immunotherapy with programmed cell death p...

pubmed.ncbi.nlm.nih.gov/31128215/

"Most surprisingly, flubendazole inhibited #PD1 levels within the tumors, but not #PDL1."